tiprankstipranks
Advertisement
Advertisement

ADCT Stock Latest News

ADC Therapeutics Balances Earnings Gains With Trial Risks
Company AnnouncementsADC Therapeutics Balances Earnings Gains With Trial Risks
16h ago
ADCT
ADC Therapeutics price target lowered to $5 from $10 at Guggenheim
PremiumThe Fly
ADC Therapeutics price target lowered to $5 from $10 at Guggenheim
8d ago
ADCT
ADC Therapeutics reports Q2 adjusted EPS (11c) vs. (25c) last year
PremiumThe Fly
ADC Therapeutics reports Q2 adjusted EPS (11c) vs. (25c) last year
8d ago
ADCT
ADC Therapeutics Reports Q2 2026 Results, Reassesses ZYNLONTA Path
PremiumCompany Announcements
ADC Therapeutics Reports Q2 2026 Results, Reassesses ZYNLONTA Path
12d ago
8K
ADCT
ADCT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ADCT Upcoming Earnings Report: What to Expect?
14d ago
ADCT
ADC Therapeutics Halts LOTIS-10 Liver-Impairment Study: What It Means for Zynlonta and Investors
PremiumCompany AnnouncementsADC Therapeutics Halts LOTIS-10 Liver-Impairment Study: What It Means for Zynlonta and Investors
1M ago
ADCT
ADC Therapeutics Grants One-Time Retention Awards to Executives
Premium
Company Announcements
ADC Therapeutics Grants One-Time Retention Awards to Executives
2M ago
8K
ADCT
ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial
Premium
The Fly
ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial
2M ago
ADCT
ADC Therapeutics Announces ZYNLONTA-Focused Strategic Reorganization
PremiumCompany Announcements
ADC Therapeutics Announces ZYNLONTA-Focused Strategic Reorganization
2M ago
8K
ADCT
ADC Therapeutics to reduce workforce by 17% globally
PremiumThe Fly
ADC Therapeutics to reduce workforce by 17% globally
2M ago
ADCT
ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
3M ago
ADCT
ADC Therapeutics price target lowered to $5 from $8 at Stephens
PremiumThe Fly
ADC Therapeutics price target lowered to $5 from $8 at Stephens
3M ago
ADCT
ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
PremiumThe FlyADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
3M ago
ADCT
ADC Therapeutics announces positive ZYNLONTA Phase 3 results
Premium
Company Announcements
ADC Therapeutics announces positive ZYNLONTA Phase 3 results
3M ago
8K
ADCT
ADC Therapeutics’ Zynlonta combination shows survival efficacy in DLBCL
Premium
The Fly
ADC Therapeutics’ Zynlonta combination shows survival efficacy in DLBCL
3M ago
ADCT
ADC Therapeutics Shareholders Back Governance and Capital Changes
PremiumCompany Announcements
ADC Therapeutics Shareholders Back Governance and Capital Changes
3M ago
8K
ADCT
Buy Rating Reiterated on Strong Execution and Pipeline Catalysts; 12-Month Price Target Maintained at $8
PremiumRatings
Buy Rating Reiterated on Strong Execution and Pipeline Catalysts; 12-Month Price Target Maintained at $8
4M ago
ADCT
ADC Therapeutics Balances Solid Quarter With Trial Risk
PremiumCompany Announcements
ADC Therapeutics Balances Solid Quarter With Trial Risk
4M ago
ADCT
ADC Therapeutics reports Q1 EPS (13c) vs. (22c) last year
PremiumThe Fly
ADC Therapeutics reports Q1 EPS (13c) vs. (22c) last year
4M ago
ADCT
ADC Therapeutics Ltd (ADCT) Q1 Earnings Cheat Sheet
PremiumPre-EarningsADC Therapeutics Ltd (ADCT) Q1 Earnings Cheat Sheet
4M ago
ADCT
ADC Therapeutics Earnings Call: Trials, Cash And Risks
Premium
Company Announcements
ADC Therapeutics Earnings Call: Trials, Cash And Risks
5M ago
ADCT
ADC Therapeutics: Strengthening Fundamentals, ZYNLONTA Pipeline Momentum, and Increased $8 Target Support Buy Rating
Premium
Ratings
ADC Therapeutics: Strengthening Fundamentals, ZYNLONTA Pipeline Momentum, and Increased $8 Target Support Buy Rating
5M ago
ADCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >